March 18, 2021 04:48 PM EDTUpdated 05:22 PM

Idera squelches any lingering enthusiasm as its lead TLR9 drug flunks PhIII — badly

John Carroll

Editor & Founder

More than 3 years ago, with its stock riding high, Idera $IDRA caused quite a stir at ESMO with its TLR9 drug and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Regeneron makes $80M obesity deal with Hansoh

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

DOGE set today as their last day at FDA. Instead, they're continuing to get full pay and don't work

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...